Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)

The prognosis of pancreatic ductal carcinoma (PDAC) with peritoneal metastasis remains dismal. Systemic chemotherapy alone may not be effective, and the combination of intraperitoneal chemotherapy with systemic chemotherapy is expected to prolong the overall survival in patients with peritoneal meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Tomohisa, Fujii, Tsutomu, Hirano, Satoshi, Motoi, Fuyuhiko, Honda, Goro, Uemura, Kenichiro, Kitayama, Joji, Unno, Michiaki, Kodera, Yasuhiro, Yamaue, Hiroki, Shimokawa, Toshio, Hashimoto, Daisuke, Yamaki, So, Yoshitomi, Hideyuki, Miura, Fumihiko, Ueno, Hideki, Sekimoto, Mitsugu, Satoi, Sohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817533/
https://www.ncbi.nlm.nih.gov/pubmed/35123553
http://dx.doi.org/10.1186/s13063-022-06049-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817533/
https://www.ncbi.nlm.nih.gov/pubmed/35123553
http://dx.doi.org/10.1186/s13063-022-06049-7

Ejemplares similares